Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced an equity inducement grant of 15,000 stock options to a new employee, effective July 26, 2021. The stock options have an exercise price of $2.86 per share, vesting over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of the Company’s 2019 Equity Incentive Plan. Bellicum focuses on developing controllable cellular immunotherapies for cancer treatment.

Positive

• New employee granted 15,000 stock options to enhance talent acquisition.
• Compliance with Nasdaq Listing Rule indicates a structured approach to employee compensation.

Negative

• None.

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grant with an effective date of July 26, 2021. The stock options were granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $2.86 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2019 Equity Incentive Plan and a stock option agreement covering the grant.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com. ​

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com

FAQ

What stock options were granted by Bellicum Pharmaceuticals on July 26, 2021?

Bellicum Pharmaceuticals granted 15,000 stock options to a new employee with an exercise price of $2.86 per share.

How do the stock options vest for the new employee at Bellicum?

The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly.

What is the significance of the stock options grant for Bellicum Pharmaceuticals?

The grant is intended as an inducement for the new employee and reflects Bellicum's commitment to attract talent.